Takeda grabs late-stage haematology drug from Protagonist February 1, 2024 AutoBot News 0 Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythemia vera (PV) treatment being developed by Protagonist Therapeutics.